Use of apomorphine in Parkinson's disease

被引:1
作者
Giménez-Roldán, S [1 ]
García-Muñozguren, S [1 ]
机构
[1] Univ Madrid, Hosp Gen Gregorio Maranon, Serv Neurol, E-28007 Madrid, Spain
关键词
apomorphine; biphasic dyskinesias; fluctuations; Parkinson's disease;
D O I
10.33588/rn.3507.2002056
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Apomorphine is a D-2 dopamine agonist, possibly underused despite its efficacy in situations where other medications have failed or lack of indication for stereotactic surgery. Rapidly effective (between 7 and 10 min) and potency approaching that of levodopa allows apomorphine to reduce reliably severe fluctuations, off-period dystonia, biphasic dyskinesias or such symptoms as dysphagia, anismus of micturition difficulties. Unlike other agonists, apomorphine has a modest capacity to induce neuropsychiatric complications. Brief duration of response (<60 min) and the need of subcutaneous administration represent major difficulties in practice. Objective and development. This review undertake some of the pharmacological properties of this 'orphan drug', its use in practice, and new pathways of development.
引用
收藏
页码:668 / 674
页数:7
相关论文
共 45 条
  • [1] ACHARD KM, 1998, BRIT J DERMATOL, V138, P480
  • [2] SUBCUTANEOUS APOMORPHINE AS A DIAGNOSTIC-TEST FOR DOPAMINERGIC RESPONSIVENESS IN PARKINSONIAN SYNDROMES
    BARKER, R
    DUNCAN, J
    LEES, A
    [J]. LANCET, 1989, 1 (8639) : 675 - 675
  • [3] APOMORPHINE TEST FOR DOPAMINERGIC RESPONSIVENESS - A DOSE ASSESSMENT STUDY
    BONUCCELLI, U
    PICCINI, P
    DELDOTTO, P
    ROSSI, G
    CORSINI, GU
    MURATORIO, A
    [J]. MOVEMENT DISORDERS, 1993, 8 (02) : 158 - 164
  • [4] RELIEF OF AKINESIA BY APOMORPHINE AND CEREBRAL METABOLIC CHANGES IN PARKINSONS-DISEASE
    BROUSSOLLE, E
    CINOTTI, L
    POLLAK, P
    LANDAIS, P
    LEBARS, D
    GALY, G
    LAVENNE, F
    KHALFALLAH, Y
    CHAZOT, G
    MAUGUIERE, F
    [J]. MOVEMENT DISORDERS, 1993, 8 (04) : 459 - 462
  • [5] CHAUDHURI KR, 1988, LANCET, V2, P1260
  • [6] CHRISTMAS TJ, 1988, LANCET, V2, P1451
  • [7] THERAPEUTIC EFFICACY OF A COMBINATION OF APOMORPHINE WITH SULPIRIDE OR METOCLOPRAMIDE IN PARKINSONISM
    CORSINI, GU
    DELZOMPO, M
    CIANCHETTI, C
    MANGONI, A
    GESSA, GL
    [J]. PSYCHOPHARMACOLOGY, 1976, 47 (02) : 169 - 173
  • [8] SIMILARITIES BETWEEN NEUROLOGIC EFFECTS OF L-DOPA AND OF APOMORPHINE
    COTZIAS, GC
    PAPAVASILIOU, PS
    FEHLING, C
    KAUFMAN, B
    MENA, I
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1970, 282 (01) : 31 - +
  • [9] TREATMENT OF PARKINSONS-DISEASE WITH APORPHINES - POSSIBLE ROLE OF GROWTH-HORMONE
    COTZIAS, GC
    PAPAVASILIOU, PS
    TOLOSA, ES
    MENDEZ, JS
    BELLMIDURA, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1976, 294 (11) : 567 - 572
  • [10] APOMORPHINE AND DIPHASIC DYSKINESIA
    DURIF, F
    DEFFOND, D
    DORDAIN, G
    TOURNILHAC, M
    [J]. CLINICAL NEUROPHARMACOLOGY, 1994, 17 (01) : 99 - 102